obesity polarization
The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed.
That can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism.
Tirzepatide, developed by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug Administration in May 2022.
This started the ‘twincretin’ era of enormously important and appealing dual therapeutic options for diabetes and obesity, as well as advanced management of closely related cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality worldwide.
Diabetes and obesity are chronic diseases leading to substantial morbidity and high mortality worldwide, especially in developed countries. They are considered the twin epidemics of the 21st century.
Neither disorder is a simple problem; rather, both are complex health issues combining genetic, epigenetic, and lifestyle factors, including socioeconomic and environmental impacts.
It should be highlighted that obesity is related to an increased risk of other serious conditions and diseases such as diabetes, hypertension, cardiovascular disease, cancer, asthma, hypercholesterolemia, and so on .
To date, the fight against obesity has been one of the greatest challenges. Treatment has been based only on a well-balanced diet and regular physical activity, so far.
Obesity are deep-rooted diseases that have no specific cure so far, but can be kept under control by proper application of therapy and treatment, as well as incorporating lifestyle modifications.
The alarming increase in the number of patients worldwide requires new scientific developments in order to ease administration, reduce the frequency of dosing, and address multiple issues within a single medication.
Tirzepatide has shown promising results in terms of reducing body weight in phase clinical trials that human clinical trials have given favorable results.
As obesity has become a global epidemic what is considered a “normal” or desirable body size has also increased, especially among certain racial-ethnic and gender groups .
A growing number of studies have found that body image is related to health behaviors including eating and dieting, particular among young people in the United States and thus affects obesity.
A full understanding of the obesity epidemic is therefore likely to include social norms along with two related mechanisms.
Now obesity issue seems to be polarized by the social rank including income and education backgrounds. Even it has rapidly become permanent.
Many types of social influences are theoretically possible, including mechanisms that do not involve norms such as market forces, advertising, neighborhood crime, and social capital.